JPWO2019241442A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019241442A5 JPWO2019241442A5 JP2020569024A JP2020569024A JPWO2019241442A5 JP WO2019241442 A5 JPWO2019241442 A5 JP WO2019241442A5 JP 2020569024 A JP2020569024 A JP 2020569024A JP 2020569024 A JP2020569024 A JP 2020569024A JP WO2019241442 A5 JPWO2019241442 A5 JP WO2019241442A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- item
- dose
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 201000003895 major depressive disease Diseases 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 10
- 206010012378 Depression Diseases 0.000 claims description 9
- 230000003920 cognitive function Effects 0.000 claims description 8
- 201000009916 postpartum depression Diseases 0.000 claims description 7
- 206010054089 Depressive symptom Diseases 0.000 claims description 6
- 206010004939 Bipolar I disease Diseases 0.000 claims description 5
- 206010004938 Bipolar disease Diseases 0.000 claims description 5
- 206010057668 Cognitive disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023205211A JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US62/684,155 | 2018-06-12 | ||
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US62/789,329 | 2019-01-07 | ||
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| US62/841,645 | 2019-05-01 | ||
| PCT/US2019/036848 WO2019241442A1 (fr) | 2018-06-12 | 2019-06-12 | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023205211A Division JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527092A JP2021527092A (ja) | 2021-10-11 |
| JPWO2019241442A5 true JPWO2019241442A5 (fr) | 2022-06-16 |
Family
ID=67211854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569024A Pending JP2021527092A (ja) | 2018-06-12 | 2019-06-12 | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2023205211A Pending JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023205211A Pending JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210338692A1 (fr) |
| EP (1) | EP3806863A1 (fr) |
| JP (2) | JP2021527092A (fr) |
| KR (1) | KR20210021005A (fr) |
| CN (2) | CN112533611A (fr) |
| AU (1) | AU2019287491A1 (fr) |
| CA (1) | CA3103421A1 (fr) |
| IL (1) | IL279315A (fr) |
| MA (1) | MA52894A (fr) |
| MX (1) | MX2020013557A (fr) |
| SG (1) | SG11202012344RA (fr) |
| TW (1) | TW202005653A (fr) |
| WO (1) | WO2019241442A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016082789A1 (fr) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions et procédés pour traiter des troubles du snc |
| JP2019524853A (ja) | 2016-08-23 | 2019-09-05 | セージ セラピューティクス， インコーポレイテッド | 結晶性１９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイド |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| KR20220112803A (ko) * | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| MX2022011804A (es) | 2020-03-25 | 2023-03-09 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias. |
| KR20230041049A (ko) * | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| AU2022238365A1 (en) * | 2021-03-17 | 2023-09-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| CA3218072A1 (fr) * | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Steroide c21-n-pyrazolyl disubstitue en c3,3 19-nor destine a etre utilise dans le traitement de la depression majeure et de la depression post-partum |
| IL307980A (en) * | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | A neuroactive steroid for use in the treatment of major depressive disorder and postpartum depression in the lactating female |
| WO2023158668A1 (fr) * | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs pour le traitement de troubles liés au snc |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2986623T1 (sl) * | 2013-04-17 | 2019-03-29 | Sage Therapeutics, Inc. | 19-NOR C3,3-disubstituirani C21-N-pirazolil steroidi in metode njhove uporabe |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016061537A1 (fr) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions et méthodes pour traiter des troubles du snc |
| CN109414444A (zh) * | 2016-03-08 | 2019-03-01 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
| JP2019524853A (ja) * | 2016-08-23 | 2019-09-05 | セージ セラピューティクス， インコーポレイテッド | 結晶性１９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイド |
| IL303250A (en) * | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
-
2019
- 2019-06-12 TW TW108120367A patent/TW202005653A/zh unknown
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/fr active Pending
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/fr unknown
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko unknown
- 2019-06-12 CA CA3103421A patent/CA3103421A1/fr active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491A1/en active Pending
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en active Pending
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507243A5 (fr) | ||
| JPWO2019241442A5 (fr) | ||
| JP2020534270A5 (fr) | ||
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2018502898A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2019508476A5 (fr) | ||
| JP2016507500A5 (fr) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2016505050A5 (fr) | ||
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| EP1383495A1 (fr) | Duloxetine pour le traitement de la bouffee de chaleur | |
| JP2018526345A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| WO2017148129A1 (fr) | Composition pharmaceutique destinée au traitement de la cachexie et son utilisation | |
| JP2023011549A5 (fr) | ||
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JP7121859B2 (ja) | 安息香酸塩または安息香酸誘導体を含む、抗ｎ－メチル－ｄ－アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 | |
| TW201244732A (en) | Ezatiostat for treating multiple myeloma | |
| RU2721409C1 (ru) | Фармацевтические комбинации ингибитора гистондеацетилаз и ингибитора протеасом или иммуномодулирующего лекарственного средства для лечения рака крови | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| Oettmeier et al. | The procaine-base-infusion: 20 years of experience of an alternative use with several therapeutical effects | |
| RU2020143245A (ru) | 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения | |
| JPWO2020023324A5 (fr) | ||
| JPS5938204B2 (ja) | 再生不良性貧血治療剤 | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона |